Q Fever – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Q Fever – Pipeline Review, H2 2017’, provides an overview of the Q Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Q Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Q Fever

The report reviews pipeline therapeutics for Q Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Q Fever therapeutics and enlists all their major and minor projects

The report assesses Q Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Q Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Q Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Q Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aradigm Corp

Grifols SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Q Fever - Overview 5

Q Fever - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Pipeline by Universities/Institutes 8

Products under Development by Companies 9

Products under Development by Universities/Institutes 10

Q Fever - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 16

Q Fever - Companies Involved in Therapeutics Development 18

Aradigm Corp 18

Grifols SA 18

Q Fever - Drug Profiles 19

ARD-3100 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

ARD-3150 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

ciprofloxacin hydrochloride - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

q fever vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Q Fever - Dormant Projects 33

Q Fever - Product Development Milestones 34

Featured News & Press Releases 34

Sep 20, 2012: UK Scientists Report Successful Testing Of Aradigm's Inhaled Liposomal Ciprofloxacin In Q Fever 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Number of Products under Development for Q Fever, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products under Development by Universities/Institutes, H2 2017 8

Products under Development by Companies, H2 2017 9

Products under Development by Universities/Institutes, H2 2017 10

Number of Products by Stage and Target, H2 2017 12

Number of Products by Stage and Mechanism of Action, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Q Fever – Pipeline by Aradigm Corp, H2 2017 18

Q Fever – Pipeline by Grifols SA, H2 2017 18

Q Fever – Dormant Projects, H2 2017 33

List of Figures

List of Figures

Number of Products by Targets, H2 2017 11

Number of Products by Stage and Targets, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports